Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept vs Placebo in SAPHO Syndrome
NCT06011889Phase 3Recruiting
- Start
- Sep 2024
- Primary completion
- Oct 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in SAPHO syndrome (SAPHO) comparing Etanercept with Placebo (2 arms). Primary endpoint: Decrease in overall disease activity and pain on Visual Analogue Scale by at least 50% at 12 weeks. Started Sep 2024; status: recruiting.
02
Drugs
etanercept
03
Conditions
SAPHO syndrome (SAPHO)
Beyond the preview
Go deeper on NCT06011889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06011889.